Cyclic guanosine monophosphate Information & Cyclic guanosine monophosphate Links at HealthHaven.com
advertise
add site
services
publishers
database
health videos
Bookmark and Share

search wiki for    ?
web dir firms image gallery news pdf wiki shop video 
about
toolbar
stats
live show
health store
more stuff
JOIN/LOGIN
Featured Results:
Zinc | Skin Care | Antioxidant | Inflammatory Regulation by Adenosine...
Zinc | Skin Care | Antioxidant | Inflammatory Regulation by Adenosine...
paulebanwell.com
  Cyclic Vomiting Syndrome
Cyclic Vomiting Syndrome
liversociety.org
 Pediatric Gems-Medical Conditions: Cyclic Vomiting Syndrome (CVS)
Pediatric Gems-Medical Conditions: Cyclic Vomiting Syndrome (CVS)
pediatricgems.com
 Pediatrics-Medical Conditions: Cyclic Vomiting Syndrome (CVS)...
Pediatrics-Medical Conditions: Cyclic Vomiting Syndrome (CVS)...
cornerstonepeds.net
 
Cyclic guanosine monophosphate
CGMP2.svg
IUPAC name
Other names cGMP; 3',5'-cyclic GMP; Guanosine cyclic monophosphate; Cyclic 3',5'-GMP; Guanosine 3',5'-cyclic phosphate
Identifiers
CAS number 7665-99-8 Yes check.svgY
PubChem 24316
MeSH Cyclic+GMP
SMILES
Properties
Molecular formula C10H12N5O7P
Molar mass 345.21 g mol−1
 Yes check.svgY (what is this?)  (verify)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Cyclic guanosine monophosphate (cGMP) is a cyclic nucleotide derived from guanosine triphosphate (GTP). cGMP acts as a second messenger much like cyclic AMP, most notably by activating intracellular protein kinases in response to the binding of membrane-impermeable peptide hormones to the external cell surface.[1]

Contents

[edit] Synthesis

cGMP synthesis is catalyzed by guanylate cyclase (GC), which converts GTP to cGMP. Membrane-bound GC is activated by peptide hormones such as the atrial natriuretic factor, while soluble GC is typically activated by nitric oxide to stimulate cGMP synthesis.

[edit] Effects

cGMP is a common regulator of ion channel conductance, glycogenolysis, and cellular apoptosis. It also relaxes smooth muscle tissues. In blood vessels, relaxation of vascular smooth muscles lead to vasodilation and increased blood flow.

cGMP is a secondary messenger in phototransduction in the eye. In the photoreceptors of the mammalian eye, the presence of light activates phosphodiesterase, which degrades cGMP. The calcium ion channels in photoreceptors are cGMP-gated, so degradation of cGMP causes calcium channels to close, which leads to the hyperpolarization of the photoreceptor's plasma membrane and ultimately to visual information being sent to the brain.[2] GMP and a number of its derivatives also have an umami taste.[3]

cGMP is also seen to mediate the switching on of the attraction of apical dendrites of pyramidal cells in cortical layer V towards semaphorin-3A (Sema3a).[citation needed] Whereas the axons of pyramidal cells are repelled by Sema3a, the apical dendrites are attracted to it. The attraction is mediated by the increased levels of soluble guanylate cyclase (SGC) that are present in the apical dendrites. SGC generates cGMP, leading to a sequence of chemical activations that result in the attraction towards Sema3a. The absence of SGC in the axon causes the repulsion from Sema3a. This strategy ensures the structural polarization of pyramidal neurons and takes place in embryonic development.

[edit] Degradation

Numerous cyclic nucleotide phosphodiesterases (PDE) can degrade cGMP by hydrolyzing cGMP into 5'-GMP. PDE 5, -6 and -9 are cGMP-specific while PDE1, -2, -3, -10 and -11 can hydrolyse both cAMP and cGMP.

Phosphodiesterase inhibitors prevent the degradation of cGMP, thereby enhancing and/or prolonging its effects. For example, Sildenafil (Viagra) enhances the vasodilatory effects of cGMP within the corpus cavernosum by inhibiting PDE 5 (or PDE V). This is used as a treatment for erectile dysfunction. However, the drug can inhibit PDE6 in retina (albeit with less affinity than PDE5). This has been shown to result in loss sensitivity but is unlikely to impair common visual tasks, except under conditions of reduced visibility when objects are already near visual threshold.[4] This effect is largely avoided by other PDE5 inhibitors, such as tadalafil.[5]

[edit] Protein kinase activation

cGMP is involved in the regulation of some protein-dependent kinases. For example, PKG (protein kinase G) is a dimer consisting of one catalytic and one regulatory unit, with the regulatory units blocking the active sites of the catalytic units.

cGMP binds to sites on the regulatory units of PKG and activates the catalytic units, enabling them to phosphorylate their substrates. Unlike with the activation of some other protein kinases, notably PKA, the PKG is activated but the catalytic and regulatory units do not disassociate.

[edit] References

  1. ^ Francis SH, Corbin JD (August 1999). "Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action". Crit Rev Clin Lab Sci 36 (4): 275–328. doi:10.1080/10408369991239213. ISSN 1040-8363. PMID 10486703. 
  2. ^ R. Lane Brown, Timothy Strassmaier, James D. Brady, Jeffrey W. Karpen (2006). "The Pharmacology of Cyclic Nucleotide-Gated Channels: Emerging from the Darkness". Current Pharmaceutical Design 12 (28): 3597–613. NIHMSID: NIHMS47625. 
  3. ^ Cairoli P, Pieraccini S, Sironi M, Morelli CF, Speranza G, Manitto P (February 2008). "Studies on umami taste. Synthesis of new guanosine 5'-phosphate derivatives and their synergistic effect with monosodium glutamate". J. Agric. Food Chem. 56 (3): 1043–50. doi:10.1021/jf072803c. ISSN 0021-8561. PMID 18181569. 
  4. ^ Stockman, A; Sharpe, LT; Tufail, A; Kell, PD; Ripamonti, C; Jeffery, G (June 2007). "The effect of sildenafil citrate (Viagra) on visual sensitivity" (Free full text). J Vis 7 (8): 4. doi:10.1167/7.8.4. PMID 17685811. http://journalofvision.org//7/8/4/. 
  5. ^ Daugan, A; Grondin, P; Ruault, C; Le Monnier De Gouville, AC; Coste, H; Linget, JM; Kirilovsky, J; Hyafil, F et al. (October 2003). "The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues". J Med Chem 46 (21): 4533–42. doi:10.1021/jm0300577. ISSN 0022-2623. PMID 14521415. 

[edit] See also




Product Results (view all...)

search wiki for    ?
web dir firms image gallery news pdf wiki shop video 



↑ top of page ↑about thumbshots